These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 29765207)
21. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665 [TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Tzefos M; Harris K; Brackett A Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377 [TBL] [Abstract][Full Text] [Related]
23. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation. Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658 [TBL] [Abstract][Full Text] [Related]
24. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect? Li Y; Rosenblit PD Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238 [TBL] [Abstract][Full Text] [Related]
25. Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes. Hamersky CM; Fridman M; Gamble CL; Iyer NN Diabetes Ther; 2019 Jun; 10(3):865-890. PubMed ID: 31054132 [TBL] [Abstract][Full Text] [Related]
26. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484 [TBL] [Abstract][Full Text] [Related]
27. Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes. d'Aquino AI; Maikawa CL; Nguyen LT; Lu K; Hall IA; Jons CK; Kasse CM; Yan J; Prossnitz AN; Chang E; Baker SW; Hovgaard L; Steensgaard DB; Andersen HB; Simonsen L; Appel EA bioRxiv; 2023 Jul; ():. PubMed ID: 36778223 [TBL] [Abstract][Full Text] [Related]
28. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. Meece J Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986 [TBL] [Abstract][Full Text] [Related]
29. Mode of administration of dulaglutide: implications for treatment adherence. Amblee A Patient Prefer Adherence; 2016; 10():975-82. PubMed ID: 27330280 [TBL] [Abstract][Full Text] [Related]
30. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Russell S Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796 [TBL] [Abstract][Full Text] [Related]
31. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Handelsman Y; Wyne K; Cannon A; Shannon M; Schneider D J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S14-S29. PubMed ID: 30156445 [TBL] [Abstract][Full Text] [Related]
32. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Shaefer CF; Kushner P; Aguilar R Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721 [TBL] [Abstract][Full Text] [Related]
33. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related]
34. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Hinnen D Diabetes Spectr; 2017 Aug; 30(3):202-210. PubMed ID: 28848315 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Karagiannis T; Liakos A; Bekiari E; Athanasiadou E; Paschos P; Vasilakou D; Mainou M; Rika M; Boura P; Matthews DR; Tsapas A Diabetes Obes Metab; 2015 Nov; 17(11):1065-74. PubMed ID: 26395850 [TBL] [Abstract][Full Text] [Related]
38. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics. García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244 [TBL] [Abstract][Full Text] [Related]
39. Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. Morieri ML; Avogaro A; Fadini GP Diabetes Metab Syndr Obes; 2020; 13():4221-4234. PubMed ID: 33204129 [TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]